aTyr Pharma (ATYR)

Executive Summary

aTyr Pharma is a clinical-stage biopharmaceutical company pioneering a novel class of immunomodulators derived from extracellular tRNA synthetases, targeting severe inflammatory and fibrotic diseases. Its lead candidate, efzofitimod (ATYR1923), is a fusion protein that modulates the immune response by binding to the neuropilin-2 receptor, showing potential in pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The company has completed Phase 1/2 trials in pulmonary sarcoidosis with encouraging safety and efficacy signals, and is currently evaluating efzofitimod in a Phase 2 trial for interstitial lung disease, which includes SSc-ILD and other fibrotic lung conditions. With a strong scientific foundation and a clear regulatory path, aTyr Pharma is positioned to address significant unmet medical needs in fibrotic and inflammatory indications, supported by its ongoing clinical programs and robust intellectual property portfolio.

Upcoming Catalysts (preview)

• Q3 2026Top-line data from Phase 2 trial of efzofitimod in interstitial lung disease (NCT05892614)70% success
• 2027Initiation of Phase 3 trial in pulmonary sarcoidosis50% success
• Q4 2026Potential FDA feedback or breakthrough therapy designation for efzofitimod60% success